Signals, Powered By EquityPandit
Zydus Cadila has received final approval to market Diclofenac Sodium Topical Solution, from the US health regulator.
It is used for treating signs and symptoms of osteoarthritis of the knees. In a BSE filing the company stated that, it is a non-steroidal anti-inflammatory drug and will be manufactured at the group’s topical manufacturing facility at Ahmedabad.
Furthermore, the company has more than 185 approvals and so far filed over 320 abbreviated new drug applications (ANDAs), since it started filings in 2003-04.
